"Drug Carriers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Forms to which substances are incorporated to improve the delivery and the effectiveness of drugs. Drug carriers are used in drug-delivery systems such as the controlled-release technology to prolong in vivo drug actions, decrease drug metabolism, and reduce drug toxicity. Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Liposomes, albumin microspheres, soluble synthetic polymers, DNA complexes, protein-drug conjugates, and carrier erythrocytes among others have been employed as biodegradable drug carriers.
| Descriptor ID |
D004337
|
| MeSH Number(s) |
D26.255.260 E02.319.300.380
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Drug Carriers".
Below are MeSH descriptors whose meaning is more specific than "Drug Carriers".
This graph shows the total number of publications written about "Drug Carriers" by people in this website by year, and whether "Drug Carriers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 6 | 2 | 8 |
| 2010 | 3 | 3 | 6 |
| 2011 | 2 | 3 | 5 |
| 2012 | 1 | 2 | 3 |
| 2013 | 2 | 5 | 7 |
| 2014 | 5 | 0 | 5 |
| 2015 | 0 | 2 | 2 |
| 2016 | 3 | 3 | 6 |
| 2017 | 2 | 1 | 3 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 2 | 3 |
| 2020 | 3 | 1 | 4 |
| 2021 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Carriers" by people in Profiles.
-
Sun H, Bhandari K, Burrola S, Wu J, Ding WQ. Pancreatic Ductal Cell-Derived Extracellular Vesicles Are Effective Drug Carriers to Enhance Paclitaxel's Efficacy in Pancreatic Cancer Cells through Clathrin-Mediated Endocytosis. Int J Mol Sci. 2022 Apr 26; 23(9).
-
Zhang D, Guo Y, Zhao Y, Yu L, Chang Z, Pei H, Huang J, Chen C, Xue H, Xu X, Pan Y, Li N, Zhu C, Zhao ZJ, Yu J, Chen Y. Expression of a recombinant FLT3 ligand and its emtansine conjugate as a therapeutic candidate against acute myeloid leukemia cells with FLT3 expression. Microb Cell Fact. 2021 Mar 10; 20(1):67.
-
Kolašinac R, Bier D, Schmitt L, Yabluchanskiy A, Neumaier B, Merkel R, Csiszár A. Delivery of the Radionuclide 131I Using Cationic Fusogenic Liposomes as Nanocarriers. Int J Mol Sci. 2021 Jan 05; 22(1).
-
Sun H, Burrola S, Wu J, Ding WQ. Extracellular Vesicles in the Development of Cancer Therapeutics. Int J Mol Sci. 2020 Aug 24; 21(17).
-
Hasan MN, Hwang YH, An JM, Shahriar SMS, Cho S, Lee YK. Oral GLP1 Gene Delivery by an Antibody-Guided Nanomaterial to Treat Type 2 Diabetes Mellitus. ACS Appl Mater Interfaces. 2020 Sep 02; 12(35):38925-38935.
-
Seaberg J, Flynn N, Cai A, Ramsey JD. Effect of redox-responsive DTSSP crosslinking on poly(l-lysine)-grafted-poly(ethylene glycol) nanoparticles for delivery of proteins. Biotechnol Bioeng. 2020 08; 117(8):2504-2515.
-
Elechalawar CK, Hossen MN, Shankarappa P, Peer CJ, Figg WD, Robertson JD, Bhattacharya R, Mukherjee P. Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro. Int J Nanomedicine. 2020; 15:991-1003.
-
Mirniaharikandehei S, VanOsdol J, Heidari M, Danala G, Sethuraman SN, Ranjan A, Zheng B. Developing a Quantitative Ultrasound Image Feature Analysis Scheme to Assess Tumor Treatment Efficacy Using a Mouse Model. Sci Rep. 2019 05 13; 9(1):7293.
-
Agrahari V, Burnouf PA, Burnouf T, Agrahari V. Nanoformulation properties, characterization, and behavior in complex biological matrices: Challenges and opportunities for brain-targeted drug delivery applications and enhanced translational potential. Adv Drug Deliv Rev. 2019 08; 148:146-180.
-
Au JL, Lu Z, Abbiati RA, Wientjes MG. Systemic Bioequivalence Is Unlikely to Equal Target Site Bioequivalence for Nanotechnology Oncologic Products. AAPS J. 2019 02 01; 21(2):24.